Medical abortion and the law
de Costa, Naomi, and de Costa, Caroline (2006) Medical abortion and the law. University of New South Wales Law Journal, 29 (2). pp. 218-223.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://www.austlii.edu.au/au/journals/UN...
[Extract] 'Medical abortion' implies the use of approved drugs to induce expulsion of a pregnancy from the uterus, the procedure taking place under medical supervision. It is thus distinguished from surgical abortion, in which instruments are used to extract the pregnancy. 'Late' medical abortion (usually from 13-21 weeks of pregnancy, but occasionally later) is practiced widely in Australia, usually in cases where a diagnosis of severe foetal abnormality has been made; such diagnoses are not yet technically· possible earlier in pregnancy. Late medical abortion is mostly performed in hospitals or clinics using the drugs gemeprost, misoprostol and others. These drugs are synthetic fonus of prostaglandins, substances occurring naturally in the body whose functions include causing contractions of the uterus. More recently, methotrexate, a drug licensed for use in Australia for treatment of psoriasis and certain cancers, has been used in combination with the prostaglandin misoprostol, and misoprostol has been used alone, to bring about earlier abortions (5-9 weeks of pregnancy). In this situation, the methotrexate is administered by injection in a clinic or surgery; subsequently (usually about two days later) the misoprostol is administered vaginally, either by the doctor or by the woman herself. The abortion then occurs at home some hours later, in a process resembling a natural miscarriage. While misoprostol is licensed for use in Australia (as elsewhere overseas) only for the treatment of stomach ulceration, both misoprostol and methotrexate are used 'off-label' for abortion. The use of drugs 'off-label' is a widely accepted practice in the medical profession and is recognised as such by the Therapeutic Goods Administration ('TGA') and similar overseas bodies, such as the United States Food and Drug Administration. The cost of making multiple applications for licensing discourages phannaceutical companies from doing so.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||medical abortion; law; surgical; Ru486|
|FoR Codes:||18 LAW AND LEGAL STUDIES > 1801 Law @ 67%|
11 MEDICAL AND HEALTH SCIENCES > 1114 Paediatrics and Reproductive Medicine @ 33%
|SEO Codes:||92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920114 Reproductive System and Disorders @ 34%|
92 HEALTH > 9205 Specific Population Health (excl. Indigenous Health) > 920507 Womens Health @ 33%
94 LAW, POLITICS AND COMMUNITY SERVICES > 9404 Justice and the Law > 940499 Justice and the Law not elsewhere classified @ 33%
|Deposited On:||16 Sep 2009 16:18|
|Last Modified:||13 Feb 2011 05:45|
Last 12 Months: 0
Repository Staff Only: item control page